Allogeneic hematopoietic stem cell transplantation in patients with therapy‐related hematologic malignancies developing after multiple myeloma-Reference-Cited by-同舟云学术

Allogeneic hematopoietic stem cell transplantation in patients with therapy‐related hematologic malignancies developing after multiple myeloma

Published:2022-02-07 Issue:5 Volume:108 Page:430-436
ISSN:0902-4441
Container-title:European Journal of Haematology
language:en
Short-container-title:European J of Haematology

Author:

Vasudevan Nampoothiri Ram¹^ORCID,Pasic Ivan¹^ORCID,Law Arjun Datt¹,Lam Wilson¹,Chen Carol¹,Michelis Fotios V.¹^ORCID,Kim Dennis (Dong Hwan)¹^ORCID,Gerbitz Armin¹,Lipton Jeffrey Howard¹^ORCID,Kumar Rajat¹,Mattsson Jonas¹,Viswabandya Auro¹

Affiliation:

1. Hans Messner Allogeneic Blood and Marrow Transplantation Program Princess Margaret Cancer Center University of Toronto Toronto Ontario Canada

Publisher

Wiley

Subject

Hematology,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/ejh.13750

Reference29 articles.

1. Surveillance epidemiology and end results (SEER) program National cancer institute. Accessed January 2021.

2. Trends in survival from myeloma, 1990–2015: a competing risks analysis

3. Risk of acute myeloid leukemia and myelodysplastic syndromes after multiple myeloma and its precursor disease (MGUS)

4. Second malignancies after multiple myeloma: from 1960s to 2010s

5. Predictors of outcomes of therapy‐related acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation;Vasudevan Nampoothiri R;Hematol Oncol Stem Cell Ther,2021

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Allogeneic hematopoietic cell transplantation is equally effective in secondary acute lymphoblastic leukemia (ALL) compared to de-novo ALL—a report from the EBMT registry;Bone Marrow Transplantation;2024-01-09

2. Impact of second primary malignancy post–autologous transplantation on outcomes of multiple myeloma: a CIBMTR analysis;Blood Advances;2023-06-15